One Step Closer to Personalized Medicine

On September 21-23, 2015, the p-medicine consortium composed of 19 partner organisations from all over Europe and Japan came together for their final project meeting in Homburg/Saar, Germany. During the meeting, the project's final achievements were presented to representatives of the European Commission, the local government as well as interested companies, research institutions and patient/parents groups.

The project’s research resulted in a series of computer-based tools, which will help cancer patients to better understand the nature of their disease and support clinicians in finding the right treatment for the individual patient by analyzing ‘big data’ from individual patients. In the end, these tools will help not only to facilitate the communication between doctors and patients and guide them to make decisions about the patient’s treatment together but will help researchers to detect new knowledge out of shared and joined health data combined with open access data.

Prof. Norbert Graf, coordinator of p-medicine, states in an interview: "The p-medicine project is facing the situation that even large diseases like breast cancer are divided into different subtypes. And each of these subtypes needs different treatment. To get these treatments to the correct patient, we need tools that are developed in p-medicine."

In the meeting's "public session", where the results of the project were presented to around 55 participants, emphasis was on the topics of patient empowerment and the progress made with regard to addressing legal and ethical requirements related to an infrastructure in which large sets of data are shared among numerous parties. Big data issues in general were also addressed by two key note speakers from Japan and the US. The public session closed with an outlook on STaRC, the Study Trial and Research Center to be found by a core team of p-medicine under the lead of Prof. Norbert Graf.

The second part of the meeting was a closed session dedicated to the evaluation of the project by the EC. The meeting ended with a very positive assessment by the EC officer and the reviewers regarding the technical implementation of the project. They particularly stressed the excellent leadership of this 19-partner project by p-medicine’s coordinator Prof. Norbert Graf.

The EU FP7 project p-medicine was one of a number of research projects arising from the broader VPH (Virtual Physiological Human) community. Research in p-medicine was devoted to creating an infrastructure that would facilitate the translation from current practice to personalised and preventive medicine. The emphasis was on formulating an open, modular framework of tools and services, so that p-medicine can be adopted gradually, including efficient secure sharing and handling of large personalized data sets and building standards-compliant tools and models. Privacy, non-discrimination, and access policies were aligned to maximize protection of and benefit to patients.

For further information, please visit:
http://www.p-medicine.eu

About p-medicine project
'p-medicine - From data sharing and integration via VPH models to personalized medicine' is a 4-year Integrated Project co-funded under the European Community's 7th Framework Programme aiming at developing new tools, IT infrastructure and VPH models to accelerate personalized medicine for the benefit of the patient.

In p-medicine 19 partners from 9 European countries and Japan have dedicated themselves to create support and sustain new knowledge and innovative technologies to overcome current problems in clinical research and pave the way for a more individualized therapy.

Most Popular Now

AI Tool Helps Predict Who will Benefit f…

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who...

Research Shows AI Technology Improves Pa…

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement disorders...

AI in Healthcare: How do We Get from Hyp…

The Highland Marketing advisory board met to consider the government's enthusiasm for AI. To date, healthcare has mostly experimented with decision support tools, and their impact on the NHS and...

Who's to Blame When AI Makes a Medi…

Assistive artificial intelligence technologies hold significant promise for transforming health care by aiding physicians in diagnosing, managing, and treating patients. However, the current trend of assistive AI implementation could actually...

First Therapy Chatbot Trial Shows AI can…

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results...

DMEA sparks: The Future of Digital Healt…

8 - 10 April 2025, Berlin, Germany. Digitalization is considered one of the key strategies for addressing the shortage of skilled workers - but the digital health sector also needs qualified...

DeepSeek: The "Watson" to Doct…

DeepSeek is an artificial intelligence (AI) platform built on deep learning and natural language processing (NLP) technologies. Its core products include the DeepSeek-R1 and DeepSeek-V3 models. Leveraging an efficient Mixture...

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...